Jump to content

Drug Industry Documents Archive

From Wikipedia, the free encyclopedia

The Drug Industry Documents Archive (DIDA) is a digital archive of pharmaceutical industry documents created and maintained by the University of California, San Francisco, Library and Center for Knowledge Management. DIDA is a part of the larger UCSF Industry Documents Library which includes the Truth Tobacco Industry Documents. The archive contains documents about pharmaceutical industry clinical trials, publication of study results, pricing, marketing, relations with physicians and drug company involvement in continuing medical education.

Most of the documents on DIDA were made public as a result of lawsuits against pharmaceutical companies Parke-Davis, Warner-Lambert, Pfizer, Merck & Co., Wyeth and Abbott Labs, among others. DIDA was founded in 2005 with the support of a gift by Thomas Greene, the attorney for David Franklin, whistleblower in United States ex rel. Franklin v. Parke-Davis, the case from which the first documents in the archive originated.[1]

Researchers as well as students, journalists, and the general public, use the archive to investigate the ways pharmaceutical companies market their products. The UCSF_Library created this digital archive in an attempt to facilitate further research into the drug industry's practice of establishing close links with the medical community which has been shown to influence scientific research, drug approval, prescription practices, and ultimately, consumer health.[2][3]

Collections

[edit]

DIDA contains:

  • internal pharmaceutical company documents
  • correspondence between drug companies and physicians, researchers and educational institutions
  • regulatory and legal documents
  • court filings
  • depositions
  • expert reports
  • internal University documents

Documents come from a variety of sources including:

References

[edit]
  1. ^ "About the Project". Drug Industry Document Archive.
  2. ^ Steinman MA, Bero LA, Chren MM, Landefeld CS (2006). "Narrative review: The promotion of gabapentin: An analysis of internal industry documents". Ann Intern Med. 145 (4): 284–93. doi:10.7326/0003-4819-145-4-200608150-00008. PMID 16908919.
  3. ^ Ross, Joseph S. (2008). "Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents from Rofecoxib Litigation". JAMA: The Journal of the American Medical Association. 299 (15): 1800–12. doi:10.1001/jama.299.15.1800. PMID 18413874.

Further reading

[edit]
[edit]